{"id":8617,"date":"2021-04-02T09:52:55","date_gmt":"2021-04-02T16:52:55","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=8617"},"modified":"2021-04-06T09:53:38","modified_gmt":"2021-04-06T16:53:38","slug":"sars-cov-2-immune-evasion-by-variant-b-1-427b-1-429","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/02\/sars-cov-2-immune-evasion-by-variant-b-1-427b-1-429\/","title":{"rendered":"SARS-CoV-2 Immune Evasion by Variant B.1.427B.1.429"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><i><span style=\"font-weight: 400\">[Pre-print, not peer-reviewed]<\/span><\/i><span style=\"font-weight: 400\"> The SARS-CoV-2 variant CAL.20C (also known as B.1.427\/B.1.429, with key mutations S13I, W152C and L452R), which was first described in California, has plasma neutralizing activity that is 3- to 4-fold lower in individuals fully vaccinated with the Moderna or Pfizer-BioNTech vaccines compared to the wild-type SARS-CoV-2 strain. Reduction in neutralizing activity among fully vaccinated individuals with prior SARS-CoV-2 infection was also similar. Neutralizing activity among individuals with prior SARS-CoV-2 infection was reduced 5-fold, but neutralizing activity was reduced to nearly undetectable levels among those with prior infection from the B.1.1.7 variant. The Regeneron monoclonal antibody (mAb) cocktail (casirivimab\/imdevimab) maintained neutralizing activity against CAL.20C compared to the wild-type strain, but 14 out of 35 mAbs tested showed reduced neutralization potency. Specifically, all mAbs targeting the N-terminal domain had abolished neutralizing activity, likely as a result of the S13I and W152C mutations.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">McCallum et al.\u00a0(Apr 1, 2021). SARS-CoV-2 Immune Evasion by Variant B.1.427B.1.429. Pre-print downloaded Apr 2 from <\/span><\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.03.31.437925\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1101\/2021.03.31.437925<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer-reviewed] The SARS-CoV-2 variant CAL.20C (also known as B.1.427\/B.1.429, with key mutations S13I, W152C and L452R), which was first described in California, has plasma neutralizing activity that is 3- to 4-fold lower in individuals fully vaccinated with the Moderna or Pfizer-BioNTech vaccines compared to the wild-type SARS-CoV-2 strain. Reduction in neutralizing activity among&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/04\/02\/sars-cov-2-immune-evasion-by-variant-b-1-427b-1-429\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-8617","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8617","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=8617"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8617\/revisions"}],"predecessor-version":[{"id":8618,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/8617\/revisions\/8618"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=8617"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=8617"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=8617"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=8617"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}